HYUNDAI PHARMACEUTICAL CO., LTD
Financials
Valuation Metrics
HYUNDAI PHARMACEUTICAL CO., LTD's Market Cap is ₩2109B. At end of 2025 it was ₩2726B. Ranked #775 of 2,405 in KR market (top 32%), #430 of 778 on KOSPI (top 55%), #85 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 210.88B KRW | KR#775/2,405 Sec#85/231 |
| Revenue | 202.33B KRW | KR#1,027/2,405 Sec#59/231 |
| Net Income | 4.18B KRW | KR#1,268/2,405 Sec#88/231 |
| Total Assets | 224.69B KRW | KR#1,231/2,405 Sec#88/231 |
| Net Assets | 128.05B KRW | KR#1,244/2,405 Sec#96/231 |
| Employees | 401 | KR#602/2,405 Sec#51/231 |
| Value | ||
| P/E | 50.49x | KR#1,422/2,405 Sec#91/231 |
| P/B | 1.65x | KR#1,865/2,405 Sec#136/231 |
| P/S | 1.04x | KR#1,465/2,405 Sec#83/231 |
| EV/EBITDA | 36.13x | KR#1,278/2,405 Sec#82/231 |
| FCF Yield | -2.24% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 3.26% | KR#1,307/2,405 Sec#90/231 |
| ROA | 1.86% | KR#1,245/2,405 Sec#90/231 |
| Op. Margin | 3.46% | KR#1,172/2,405 Sec#86/231 |
| Revenue Growth | 12.04% | KR#797/2,405 Sec#79/231 |
| Financial Health | ||
| Debt Ratio | 75.47% | KR#1,282/2,405 Sec#154/231 |
| Total Debt | 49.55B KRW | KR#1,009/2,405 Sec#71/231 |
| FCF | -4.73B KRW | KR#1,480/2,405 Sec#117/231 |
| Cash | 7.69B KRW | KR#1,828/2,405 Sec#162/231 |
| Current Ratio | 1.69x | KR#1,036/2,405 Sec#117/231 |
| Net Debt/EBITDA | 5.98x | KR#1,081/2,405 Sec#82/231 |
| Dividend | ||
| Div. Yield | 0.46% | KR#1,289/2,405 Sec#81/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | 78.35% | KR#99/2,405 Sec#4/231 |
| 1M Return | -20.98% | KR#1,924/2,405 Sec#189/231 |
| From 52W High | -58.71% | KR#1,599/2,405 Sec#132/231 |
| 1Y MDD | -68.41% | KR#1,886/2,405 Sec#160/231 |
| Trading | ||
| Volume | 220,224 shares | KR#335/2,405 Sec#23/231 |
| Trading Value | 1.45B KRW | KR#494/2,405 Sec#48/231 |
| Foreign Own. | 0.96% | KR#2,041/2,405 Sec#200/231 |
| Per Share | ||
| EPS | 131 KRW | KR#1,387/2,405 Sec#93/231 |
| BPS | 4,002 KRW | KR#1,681/2,405 Sec#123/231 |
Company Info
Hyundai Pharmaceutical, established in 1965 and listed on the stock market in 1978, is a pharmaceutical and beverage manufacturing and sales company. It produces and supplies both specialized prescription drugs (such as hypertension treatment Tenormin) and over-the-counter drugs (like alopecia treatment Minoxidil Solution and mosquito bite relief Burmuli) to hospitals, clinics, and pharmacies nationwide. The company is currently conducting Phase 2b clinical trials for HDNO-1605, an innovative new drug for diabetes, and actively seeking improved new drugs to enhance medication adherence in the cardiovascular sector. Hyundai Pharmaceutical is headquartered in Cheonan-si, Chungcheongnam-do.